What do Microsoft, Aetna, Twitter, IBM, Ogilvy Consulting, Biogen and dozens of healthcare startups have in common? All appear in discussions about issues at the nexus of healthcare and technology in Icons.Health, a new video series produced by AbelsonTaylor.
Two leading longevity biotechnology companies, Elevian and Insilico Medicine, announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets.
Three leading health and pharmaceutical companies – GlaxoSmithKline, Teva, Takeda – and EcoVadis, the leading provider of sustainability risk and performance ratings for global supply chains, announced the launch of the Responsible Health Initiative.
Adaptive Biotechnologies announced a worldwide collaboration and license agreement with Genentech – a member of the Roche Group – to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers.
Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).
Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, and KingMed Diagnostics, a laboratory services leader in China, announced that they have entered into a strategic partnership for the PGDx elioTM tissue complete assay.
Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration expanded the indication for Sprycel tablets to include the treatment of pediatric patients 1 year of age and older with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in combination with chemotherapy.
Ironwood Pharmaceuticals Inc. and Allergan plc announced that the companies reached an agreement with Mylan Pharmaceuticals Inc. resolving patent litigations brought in response to Mylan’s abbreviated new drug applications seeking approval to market generic versions of Linzess (linaclotide) before the expiration of the companies’ applicable patents.
Kala Pharmaceuticals Inc. announced that the New Drug Application (NDA) for KPI-121 0.25%, a product candidate for the temporary relief of signs and symptoms of dry eye disease utilizing a two-week course of therapy, has been accepted for review by the United States Food and Drug Administration FDA.
Global biopharmaceutical company AbbVie Inc. licensed pharma major Lupin Limited’s MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program.
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
December 2018 Focus: Healthcare Agency Roundtable, Mobile Marketing, and more!
